1. Generics Bulletin
  2. >>Business

Nichi-Iko Offers Heartfelt Apology As It Forecasts Huge Annual Loss

As Analyst Warns: Pharmacies And Medical Institutions ‘May Start To Desert Nichi-Iko’

 
• By Dean Rudge

Nichi-Iko’s first-half financial results made for unhappy reading again as the company’s bottom line was battered by longstanding quality problems, leading the firm to announce huge projected losses for its current financial year ending in March 2022.

Japan Flag Graph Figures Downward Trend Numbers
Production 'is taking longer than expected' • Source: Alamy

Nichi-Iko Pharmaceutical Co., Ltd. has apologized to shareholders “from the bottom of our heart” after once again taking the axe to its full-year profit guidance, this time conceding that the Japanese firm is braced for losses in the tens of billions of yen due largely to deep-seated supply issues at the company’s key Namerikawa plant in the Toyama prefecture.

The new guidance came as Nichi-Iko reported an ¥8.79bn ($76

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.